文献速递心境障碍儿童青少年精神

孕期锂暴露与母婴结局:六项队列研究国际协作meta分析

Maternal and infant outcomes associated with lithium use in pregnancy: an international collaborative meta-analysis of six cohort studies.
PubMed 文献 · Lancet Psychiatry · 2018-06-18

BACKGROUND: Concerns about teratogenicity and maternal and offspring complications restrict the use of lithium during pregnancy for the treatment of mood disorders.…

核心结论

  • 锂暴露未增加预设妊娠并发症及分娩结局风险,但新生儿28天内再入院及孕早期重大畸形风险升高。
  • 治疗决策需权衡孕期锂暴露的潜在风险与其减少复发的获益。

研究设计与样本

  • 国际协作meta分析,汇总六项队列(丹麦、瑞典、加拿大安大略;荷兰、英国、美国)的原始数据。
  • 纳入1997至2015年间活产单胎、母婴健康信息完整、母亲有心境障碍或孕期锂暴露的妊娠,排除使用已知致畸药物的妊娠。
  • 采用共享方案在各站点分析,逻辑回归计算调整OR(aOR)及95%CI,随机效应模型汇总。

主要发现

  • 锂暴露与任何预设妊娠并发症或分娩结局均无关联。

关键数值与推荐

  • 锂暴露定义:孕前1个月至分娩期间至少两次锂取药,或孕期单次取药且前后6个月内有另一次锂取药。
  • 主要结局:妊娠并发症、分娩结局、新生儿出生28天内再入院、重大畸形及重大心脏畸形。
  • 效应量:汇总aOR及95%CI,随机效应模型。

临床怎么用

  • 对心境障碍孕妇使用锂时,应个体化权衡孕早期重大畸形及新生儿再入院风险与减少复发的获益。
  • 孕早期锂暴露需加强产前畸形筛查及新生儿监护。

局限性

  • 原文未报告局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Concerns about teratogenicity and maternal and offspring complications restrict the use of lithium during pregnancy for the treatment of mood disorders. We aimed to investigate the association between in-utero lithium exposure and risk of pregnancy complications, delivery outcomes, neonatal morbidity, and congenital malformations. METHODS: In this meta-analysis, primary data from pregnant women and their children from six international cohorts based in the community (Denmark, Sweden, and Ontario, Canada) and in clinics (the Netherlands, UK, and USA) were analysed. Pregnancies were eligible for analysis if the pregnancy resulted in a liveborn singleton between 1997 and 2015, if health-related information was available for both mother and infant, and if the mother had a mood disorder (bipolar disorder or major depressive disorder) or if she had been given lithium during pregnancy (at least two dispensations of lithium during pregnancy that were dispensed any time from 1 month before conception until the delivery, or a single lithium dispensation during pregnancy when there was at least one other lithium dispensation within 6 months before or after this date). Pregnancies during which the mother had been prescribed known teratogenic drugs were excluded. Pregnancies were grouped into a lithium-exposed group and a mood disorder reference group. The main outcome measures were pregnancy complications, delivery outcomes, neonatal readmission to hospital within 28 days of birth, and congenital malformations (major malformations and major cardiac malformations). Analyses were done at each site by use of a shared protocol. Adjusted odds ratios (aORs) and 95% CIs were calculated by use of logistic regression models, and site-specific prevalence rates and ORs were pooled by use of random-effects meta-analytical models. FINDINGS: 22 124 eligible pregnancies were identified across the six cohorts, of which 727 pregnancies were eligible for inclusion in the lithium-exposed group (557 [77%] from register-based cohorts and 170 [23%] from clinical cohorts). Lithium exposure was not associated with any of the predefined pregnancy complications or delivery outcomes. An increased risk for neonatal readmission within 28 days of birth was seen in the lithium-exposed group compared with the reference group (pooled prevalence 27·5% [95% CI 15·8-39·1] vs 14·3% [10·4-18·2]; pooled aOR 1·62, 95% CI 1·12-2·33). Lithium exposure during the first trimester was associated with an increased risk of major malformations (pooled prevalence 7·4% [95% CI 4·0-10·7] vs 4·3% [3·7-4·8]; pooled aOR 1·71, 95% CI 1·07-2·72) but for major cardiac malformations the difference was not significant (2·1% [0·5-3·7] vs 1·6% [1·0-2·1]; pooled aOR 1·54, 95% CI 0·64-3·70). INTERPRETATION: Considering both the effect sizes and the precision of the estimates in this meta-analysis, treatment decisions for pregnant women with mood disorders must weigh the potential for increased risks of lithium during pregnancy-in particular those associated with use of lithium during the first trimester-against its effectiveness at reducing relapse. FUNDING: None.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Munk-Olsen T, Liu X, Viktorin A, et al. Maternal and infant outcomes associated with lithium use in pregnancy: an international collaborative meta-analysis of six cohort studies. Lancet Psychiatry. 2018. PMID: 29929874. doi:10.1016/S2215-0366(18)30180-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。